VACCINE AFFECT

In this article researchers review advances in 3 areas regarding drug hypersensitivity

This study utilised the WHO international pharmacovigilance database, vaccine-associated pericarditis and myocarditis: 1969 and 2023

This study was aimed at clarifying the association between covid-19 mRNA vaccines and myocarditis/pericarditis

Clinical trials are conducted under widely varying conditions and may not reflect the rates observed in practice.

Clinical trials are conducted under widely varying conditions and may not reflect the rates observed in practice.

Saftely concerns of epigenic and genomic modifications

According to the Pfizer and Moderna trials, infection rates for covid-19 at its peak without and with vaccines were 0.75-1.22% and 0.04-0.07

Messenger RNA (mRNA) vaccines have been in development since the 1960s

Serious adverse events following mRNA COVID-19 vaccination

8 October 2024

Whooping cough and flu. Despite the routine immunisation with whole cell pertussis (wP) and acellular pertussis (aP) vaccine, pertussis rema

Global and regional burden of vaccine-associated facial paralysis, 1967–2023: Findings from the WHO international pharmacovigilance database

Global burden of vaccine-associated multiple sclerosis, 1967–2022: A comprehensive analysis of the international pharmacovigilance database

Global burden of vaccine-associated anaphylaxis and their related vaccines, 1967–2023